Abstract #2913
MRI of Calu-6 lung tumors for the assessment of the anti-vascular activity of MN-029
Genne P, Guilbaud N, Locke K, Just N, Rancier V
Oncodesign Biotechnology
In this study, we characterized the changes in perfusion of subcutaneously xenografted Calu-6 human lung tumors following intravenous infusion of rats with a novel vascular disrupting agent (MN-029). We observed that in rats treated with 10 mg/kg MN-029, tumor Ktrans and extravascular-extracellular volume (ve) parameters were significantly smaller one and three hours post-treatment compared to values obtained before treatment and compared to vehicle-treated rats. Immunohistochemical studies performed after injection of fluorochromes confirmed these results.